Cambium Bio Forms Partnership With French Pharmaceutical Firm; Shares Up 4%

MT Newswires Live
2025/09/05

Cambium Bio (ASX:CMB) entered into a memorandum of understanding with Benta, a French pharmaceutical company, to establish a strategic partnership to develop and commercialize Elate Ocular for dry eye disease in Europe and the Middle East, according to a Friday Australian bourse filing.

The company said the partnership will provide access to major European and Middle Eastern markets. Under the deal, Benta will facilitate exchanges with regulators in France and Europe, the Middle East, and Africa.

The company's shares rose past 4% in recent Friday trade.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10